Differential Binding of Inhibitors to Active and Inactive CDK2 Provides Insights for Drug Design  by Kontopidis, George et al.
Chemistry & Biology 13, 201–211, February 2006 ª2006 Elsevier Ltd All rights reserved DOI 10.1016/j.chembiol.2005.11.011Differential Binding of Inhibitors
to Active and Inactive CDK2
Provides Insights for Drug DesignGeorge Kontopidis,1,4,* Campbell McInnes,1,4
Sravan R. Pandalaneni,1,3 Iain McNae,2
Darren Gibson,1 Mokdad Mezna,1 Mark Thomas,1
Gavin Wood,1 Shudong Wang,1
Malcolm D. Walkinshaw,1,2 and Peter M. Fischer1
1Cyclacel Ltd.
James Lindsay Place
Dundee, DD1 5JJ
United Kingdom
2Structural Biochemistry
The University of Edinburgh
Michael Swann Building
King’s Buildings
Edinburgh, EH9 3JR
United Kingdom
3University of Abertay
Dundee, DD1 1HG
United Kingdom
Summary
The cyclin-dependent kinases (CDKs) have been char-
acterized in complexwith a variety of inhibitors, but the
majority of structures solved are in the inactive form.
We have solved the structures of six inhibitors in both
the monomeric CDK2 and binary CDK2/cyclinA com-
plexes and demonstrate that significant differences in
ligand binding occur depending on the activation
state. The binding mode of two ligands in particular
varies substantially in active and inactive CDK2. Fur-
thermore, energetic analysis of CDK2/cyclin/inhibitors
demonstrates that a good correlation exists between
the in vitro potency and the calculated energies of
interaction, but no such relationship exists for CDK2/
inhibitor structures. These results confirm that mono-
mericCDK2 ligandcomplexesdonot fully reflect active
conformations, revealing significant implications for
inhibitor design while also suggesting that the mono-
meric CDK2 conformation can be selectively inhibited.
Introduction
CDKs fulfill numerous and partly overlapping functions
in the regulation of both the cell proliferation cycle and
the RNA polymerase-II (RNAP-II) transcription cycle [1].
However, the demonstration that CDK2 activity appears
to be redundant for the proliferation of normal cells [2],
and in some cases of cancer cells [3], has led to ques-
tions regarding the validity of CDK2 as a drug target for
proliferative diseases [4, 5]. Nevertheless, the potential
of pharmacological CDK2 inhibition in suppressing cell
proliferation remains to be explored. At present, appro-
priate mechanistic questions are difficult to answer be-
cause small-molecule inhibitors invariably also suppress
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4 These authors contributed equally to this work.CDKs other than CDK2, especially CDK1, which regu-
lates entry into mitosis, as well as CDK7 and CDK9 [6].
The latter two CDKs have been implicated in the regu-
lation of RNAP-II activation in addition to their cell cycle-
related functions [7–9]. The expression of many genes is
regulated at the level of RNA transcription, and CDK7
and CDK9 form part of the general transcription factors
TFIIH and p-TEFb, respectively, in which they activate
RNAP-II through phosphorylation of its C-terminal do-
main (CTD). Other members of the CDK family, including
CDK1, CDK8, and especially CDK2, that were originally
ascribed cell cycle functions only, are now known to par-
ticipate in the regulation of RNAP-II[10]. Transformed
cells require continuous activity of RNAP-II to resist on-
cogene-induced apoptosis [11], and a new oncology
CDK target rationale based on inhibition of transcription
has been proposed [12].
Despite the complexities of their mechanism of
action, CDKs remain the focus of intense efforts in drug
development. Several inhibitors with activity against
CDKs are currently under clinical examination in cancer
research [13–16].
Here, we shall confine our analysis to CDK2, the best-
characterized member of the CDK family in terms of
structural biology. It is known that binding of cyclins A
and E induces a structural reorganization in CDK2 that
is necessary for activation [17, 18]. The reorganization
is believed to be a two-step process [19]. First, the
PSTAIRE helix of CDK2 is bound between the a3 and
a5 helices of cyclin A, followed by additional contacts
of cyclin A with the C-terminal lobe of CDK2. Monomeric
CDK2 has virtually no activity; however, when phosphor-
ylated, it has been shown to possess about 1% of the
activity of the fully active binary complex (16 versus
1600 pmol$min21$mg21) [20, 21]. As in many protein ki-
nases, the inactive conformation occurs when, in the ab-
sence of posttranslational modification, the catalytic
and substrate binding sites are occluded, or inappropri-
ately aligned for phosphotransferase activity [22]. For
CDK2, partnering with cyclins A or E results in rotation
of the PSTAIRE helix by 45º relative to the monomeric
enzyme. While some kinases are catalytically competent
in the phosphominus state, an activation step involving
phosphorylation of a tyrosine-, serine-, or threonine-
containing loop is required in order to produce the acti-
vated enzyme. In the CDK2/cyclin A or CDK2/cyclin E
complex, the activation loop is relocated from the phos-
phoacceptor and ATP binding sites to interact with the
cyclin, in a movement of approximately 25 A˚. Subse-
quent phosphorylation at T160 by the CDK-activating ki-
nase (CAK; a complex of CDK7, cyclin H, and MAT-1) re-
sults in stabilization of the cyclin bound CDK2 structure
and generation of the fully active conformation. Together
this process results in the formation of a catalytically
competent ATP cleft and substrate binding site [23].
CDK2 is one of the best-characterized kinases in
structural terms, and there exist approximately 70
X-ray crystal structures of CDK2 inhibitor complexes in
the Protein Data Bank (PDB). A wealth of structural
data is thus available for analysis and use in the further
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202Table 1. Chemical Structures, In Vitro Inhibition, and Comparison of the Calculated Energetics for CDK2 Inhibitors in Monomeric and Activated
Complexes
1 2 3 4 5 6
CDK2 CDK2A CDK2 CDK2A CDK2 CDK2A CDK2 CDK2A CDK2 CDK2A CDK2 CDK2A
IC50 (mM) 6.50 6.50 0.29 0.29 0.22 0.22 0.01 0.01 0.74 0.74 0.25 0.25
NB energy 245.3 227.8 241.1 260.2 257.6 258.1 237.3 272.5 282.0 240.3 256.7 251.6optimization and development of ATP-competitive com-
pounds [15]. Of these structures, however, only about
20% contain the activated CDK2 kinase state. In addi-
tion, the coordinates of only two structures with ATP-
competitive ligands, the purine derivative NU2058 [24]
and an oxindole derivative [25], were deposited in the
PDB as both CDK2 and CDK2/cyclin A complexes. In
the latter case, however, different oxindoles were used
in the monomeric and activated CDK2 structures. A re-
cent study described a structural comparison with indir-
ubin 5-sulfonate as the ligand in both inactive and active
forms of CDK2 [26]. The main conclusions were: (1) the
adenine binding site of CDK2 was similar in both forms,
and the inhibitor made comparable contacts in this re-
gion; (2) residues outside of this region, including resi-
dues of the Gly-rich loop and the side chains of K33
and D145, have different positioning, and therefore
make different contacts with the ligand, in the mono-
meric and binary complexes. These conclusions were
made on the basis of only one CDK2 ligand, and addi-
tional comparisons of these data are not possible, as
only the activated kinase inhibitor structure was depos-
ited in the PDB. We have solved six CDK2 ligands based
on the previously described 2-anilino-4-(hetero)aryl-py-
rimidine pharmacophore [27, 28] in both monomeric and
cyclin A bound CDK2 complexes. These structures
show that, depending on the size and substitution of
the ligand core structure, significantly different inhibitor
binding modes are observed in each context. In addi-
tion, a detailed study of the existing data from several
of the currently available CDK2 structures is presented
comparing the energetics of binding and protein/ligand
contacts of inhibitors in active and inactive CDK2 con-
formations. We thus give a comprehensive picture of
the structural differences that occur upon ligand binding
to both activation states and outline the implications for
CDK2 inhibitor discovery and design.
Results
Affinity of CDK2 Inhibitors for Active
and Inactive Conformations
The X-ray crystal structures of six CDK2 inhibitors in
complex with both monomeric and CDK2/cyclin com-
plexes have been determined, and their structure statis-
tics are summarized in Table S1 (see the Supplemental
Data available with this article online). An extensive anal-
ysis of these complexes and of other published CDK2inhibitors bound to monomeric inactive and cyclin acti-
vated forms has been carried out to determine the rela-
tive binding affinity for inhibitors in both states (Table 1).
A total of 17 inactive and 17 active CDK2 inhibitor struc-
tures (with 6 novel and 11 from the PDB in both CDK2
conformations) possessing a wide range of potencies
in the CDK2/cyclin kinase assays were selected, and
the protein/ligand interaction energy was determined.
This involved the addition of hydrogens to the PDB
structure, followed by a minimization routine keeping
all heavy atoms of the protein and ligand fixed, followed
by interaction energy calculation. Furthermore, the cor-
relation between the calculated energetics of the com-
plexes and the experimentally derived inhibition con-
stants was examined to ascertain if the monomeric
inhibitor complex structure was an accurate reflection
of the active CDK2 complex.
This analysis indicates that there is a minimal correla-
tion between inhibitor potency and calculated binding
affinity for the inactive enzyme, both for compounds 1–
6 (Table 1) and for the PDB ligands in complex with mo-
nomeric CDK2 (Figures 1A and 1C). An excellent correla-
tion is observed, however, for the set of cyclin-activated
CDK2 inhibitor structures. The relationship between the
interaction energies and the IC50 values for compounds
1–6 is close to linear, with a correlation coefficient value
of 0.85 (Figure 1B). When the data calculated from the
PDB structures are included in the analysis, a slightly
lower correlation of 0.75 is observed for the active struc-
tures (Figure 1D). The new CDK2/cyclin A structures
containing pyrimidine-based inhibitor ligands thus fur-
ther extend and confirm the relationship observed for
the diverse ligand group from the PDB. The correlations
obtained above are supported by protein/ligand affinity
calculations with the LUDI and LigScore1 scoring func-
tions (data not shown), which gave similar results. In ad-
dition, the surface area buried upon ligand binding was
measured for both sets of structures by calculating the
solvent-accessible surface area for the free ligand and
protein/ligand complex. These results again demon-
strated a close relationship between inhibitor potency
and buried surface area in the CDK2/cyclin bound struc-
tures, in contrast with the lack of correlation for the mo-
nomeric data set (see Supplemental Data).
Given that a strong correlation exists between the en-
zyme/ligand intermolecular energies and the biochemi-
cal ligand inhibition constants in the case of the active
CDK2 complex structures (Figures 1B and 1D), it is
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203Figure 1. Correlation of Calculated Interac-
tion Energies with Experimental Inhibition
Constants
(A–D) Graphs for pyrimidine analogs 1–6
alone ([A], monomeric; [B], active), and in-
cluding a set of diverse CDK2 inhibitors
from the PDB ([C], monomeric; [D], active)
in inactive monomeric and active cyclin
bound structures.reasonable to extrapolate values obtained from the crys-
tal structures to determine the relative affinities for the
active and inactive forms. Analysis of the data indicates
that the ligands NU2058 (246.9 versus 255.1 kcal/mol)
and ATP (2276 versus 2672 kcal/mol) would be ex-
pected to form tighter complexes with monomeric
CDK2.
Extending this affinity analysis for compounds 1–6
shows that the least potent inhibitor 1 has significantly
higher affinity for the monomeric species, while the bind-
ing energetics predict that of the more potent com-
pounds, 5 and 6 also form tighter complexes with inac-
tive CDK2. Compounds 2 and 4, on the other hand,
bind more avidly to active CDK2/cyclin A, as evidenced
by the more favorable energy scores. Compound 3
could be considered to have equal affinity for both active
and inactive CDK2 states within the levels of accuracy of
the energetics calculation.
In addition to this analysis from CDK2/ligand struc-
tures that have been solved in both their inactive and ac-
tive states, the theoretical binding constants of an addi-
tional set of inhibitors were calculated based on their
nonbonded energies in the monomeric CDK2 crystal
structures extrapolated from the active CDK2 inhibitor
correlation (Table 2). This is informative given that no ex-
perimental data are available for binding of these inhib-
itors to the monomeric inactive CDK2. The accuracy of
this calculation is valid, since, as shown above in the
context of the active enzyme, interaction energies gave
a good indication of the experimental inhibition constant
(Figures 1B and 1D). These results indicate that 5 out of
the 11 CDK2 inhibitors whose affinities were calculated
in this way bind with significantly higher affinity to themonomeric enzyme, whereas 4 additional compounds
bind with similar potency within the levels of accuracy.
Inhibitor Binding Modes Differ in Monomeric
and Cyclin Bound CDK2
To characterize the conformational differences that oc-
cur in CDK2 upon activation and to determine the impact
of these differences upon protein/ligand interactions, we
have solved the structures of six CDK2 inhibitors by X-
ray crystallography in both the monomeric and cyclin
bound activated complexes. In general, from the CDK2
inhibitor complex structures, the side chains of residues
E51, V64, D145, and L148, as well as atoms of residues
10–15 of the Gly-rich loop, adopt different positions in
active and inactive CDK2 (Figure 2A). In addition, the cat-
alytic lysine, K33, assumes different conformations in
the two structures, and, as a result of activation of
CDK2 through cyclin binding and subsequent rotation
of the PSTAIRE helix, E51 moves and occupies the
space where L148 is found in the inactive CDK2 struc-
ture. The largest movement of the residues comprising
the ATP binding cleft of CDK2 is that of D145, which
moves by 1–2 A˚ upon activation. Initial analysis of these
differences indicates that they would not be expected to
have a significant effect on ligand binding, as has been
suggested for similar inhibitors bound to both forms of
CDK2 [24, 25, 29].
This new data set comprises ligands of varying poten-
cies (Table 1), details the extent of interactions with the
ATP binding site, and demonstrates that important vari-
ations in the CDK2/ligand interactions and binding mode
exist between the two states. These inhibitors are simi-
lar, with the exception of 1, which lacks the phenylTable 2. Calculation of Binding Constants for CDK2 Inhibitors in the Monomeric Form
1H08 1JSV 1JVP 1KE5 1KE6 1OIR 1P2A 1AQ1 1DM2 1E1V 1E1X
NB EGY 270.9 260.0 240.3 274.7 276.2 285.6 264.8 279.9 259.1 255.1 234.4
Exp. IC50 (mM) 0.300 2.000 1.600 0.560 0.006 0.032 0.012 0.007 0.040 0.300 0.300
Calc. IC50 (mM) 0.023 0.170 6.120 0.011 0.009 0.002 0.069 0.004 0.195 0.410 17.890
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(A) Active apo-CDK2 is shown in yellow; inactive apo-CDK2 is shown in blue. The differences in the orientation of the N and C domains and in the
large movement of the T-loop upon cyclin binding can be observed upon overlay of the active and inactive structures from residues 170–285.
(B) Electron density difference maps (2Fo 2 1Fc) in the ATP binding site of the CDK2/cyclin A/4 complex.substituent on the pyrimidin-2-yl amino group, and 6, in
which the thiazole group is replaced with a [1,2,4]triazol-
1-ylmethyl-phenyl system. The CDK2 binding mode of
the 2-anilino-4-(thiazol-5-yl)pyrimidine pharmacophore
has previously been described (Figure 2B and Figure S1)
[28, 30] and includes the following contacts: (1) for the
pyrimidine ring: a hydrophobic sandwich between A31
and L134, an H bond between the hinge region residue
L83 backbone NH and N1 of the pyrimidine, and an aro-
matic H-CO interaction between the pyrimidine C6 pro-
ton and E81; (2) van der Waals contacts from the aniline
ring to the side chain of I10, an H bond between the an-
iline NH and the L83 carbonyl, and, depending on substi-
tution, varying contacts to Q85, D86, and K89; and, (3) in-
teractions of the thiazole ring with V18, as well as direct
contacts of the thiazole 4-methyl with the F80 gate-
keeper residue. The thiazole 2-position projects toward
the cleft region occupied by the ATP triphosphate.
In order to further investigate the contributions of the
protein/ligand interactions to binding in the inactive
and active contexts, a detailed contact and energetic
analysis for each small-molecule inhibitor was per-
formed (Table 3). Of the new ligand structures pre-
sented, the largest observed conformational differences
occurred with compound 1 (Figure 3). The NH2 group of
the ligand forms an H bond with the backbone carbonyl
of E81 in inactive CDK2. In the active complex, however,
the pyrimidine ring flips by 180º, resulting in an inter-
action of the amino group with the L83 carbonyl. This
corresponds to a relative movement of more than 4 A˚
for both rings of the inhibitor. More favorable interac-
tions are observed with I10 and with K33 in the mono-
meric CDK2 as a result of close contacts of the pyrimi-
dine and thiazole rings, respectively. In active CDK2,
the thiazole system interacts more favorably with F80
(Table 3), packing against its aromatic ring and resulting
in displacement of K33 in order to bind similarly to the
anilino derivatives (compounds 2–5).For compounds 2–5, similar binding modes are found
in both the active and inactive proteins (Figures 4A and
4B); however, the major differences in the interactions
of each segment of the inhibitor are described as follows.
Aniline Region
Significantly different interactions are observed from
this part of the inhibitor and the residues of the Gly-
rich loop in the activated CDK2. Residues I10, G11,
and E12 show variations in energetics between active
and inactive CDK2, especially with inhibitors 2, 4, and
5 (Table 3). Inhibitors 2 and 4 make significantly more fa-
vorable interactions with I10 in the cyclin bound CDK2
due to the closer contacts of the aniline phenyl ring.
Also, 4 associates with G11 in the active context through
movement of the Gly-rich loop closer to the ligand. Anal-
ysis of the contacts with the hinge region and specificity
surface (C-lobe loop region of the ATP site) in both CDK2
forms reveals major differences. Firstly, the hinge region
undergoes a ligand-induced movement, and this results
in significantly different interactions and energetics for
some of the inhibitors. In particular, the H84 carbonyl
and the Q85 CA shift toward the inhibitor in the active
CDK2. This generally results in more favorable interac-
tions of L83 with the anilino function, but it is offset by
bad contacts with H84, Q85, and D86 (Table 3) in com-
pounds containing a para-substituted aniline (2, 3, and
5). Secondly, compounds containing bulky para substit-
uents (p-dimethylamino, 3; p-morpholine, 5) make detri-
mental interactions with K89 in active CDK2 compared
to the smaller substitutions (m-nitro, 4, and p-CF3, 2).
In particular, the p-morpholine of 5 overlaps with K89
and results in movement of the ligand closer to L83,
making the H bonding energies with the aniline NH unfa-
vorable. Movement of the ligand as a result of the large
substitution forces it to adopt a different conformation
distant from the unfavorable site. The consequence of
this is relative movement of the thiazole by more than
1 A˚.
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205Table 3. Calculated Intermolecular Energetic Values for CDK2 Residues and Compounds 1–6
CDK2 Residue 1Ma,b 1C 2M 2C 3M 3C 4M 4C 5M 5C 6M 6C
E8 211.0 20.1 20.3 20.2 0.2 0.2 20.7 20.5 20.8 20.3 0.0 20.3
I10 21.5 20.4 22.7 23.7 23.9 24.1 22.7 23.6 24.2 24.4 23.6 23.0
G11 20.6 0.0 20.2 20.9 20.1 20.2 20.4 21.5 20.3 20.3 21.2 20.6
E12 21.4 21.0 20.1 20.8 20.3 0.3 0.6 0.4 20.4 21.0 1.4 0.4
G13 20.7 20.7 20.3 20.2 20.5 20.2 20.1 20.8 20.3 20.5 7.4 20.1
V18 21.9 21.5 21.5 0.3 22.0 22.1 21.5 22.1 21.5 21.7 22.9 21.9
A31 20.6 21.2 21.0 20.6 21.5 20.5 21.3 21.1 21.2 21.6 21.8 20.1
K33 25.0 22.4 23.2 24.6 22.5 21.0 23.6 24.8 25.7 24.3 24.2 21.4
E51 0.2 20.2 0.1 0.5 0.1 20.5 0.2 1.4 0.1 0.9 0.0 21.1
V64 20.3 20.7 20.8 20.6 20.8 20.6 20.7 20.9 20.8 20.6 20.3 21.0
F80 20.8 22.0 21.5 21.6 21.7 22.3 21.3 22.1 21.6 21.4 22.5 22.9
E81 20.8 0.2 22.2 21.0 20.2 21.1 20.7 21.9 20.5 21.8 20.3 1.8
F82 22.5 22.5 21.9 23.8 24.1 23.4 23.1 21.9 23.5 23.9 23.6 22.2
L83 22.1 21.2 2.8 23.1 21.2 22.6 23.0 23.9 1.6 3.0 1.1 22.5
H84 20.3 20.4 20.6 20.5 21.6 20.6 21.6 21.7 21.4 2.8 21.6 21.5
Q85 20.1 20.2 21.7 0.9 22.4 21.7 21.6 21.6 22.4 0.7 21.7 21.7
D86 20.6 22.0 22.7 21.1 22.0 20.9 21.1 21.6 22.4 20.9 21.8 20.9
K89 0.9 0.9 21.8 22.9 1.1 0.5 3.6 20.6 22.3 21.7 1.5 20.6
Q131 20.5 20.3 20.8 20.4 21.1 20.2 20.9 20.6 20.5 20.2 21.5 20.2
N132 20.6 20.4 20.7 20.5 21.1 20.3 20.8 20.4 20.7 20.2 20.8 1.8
L134 21.0 0.2 21.6 20.2 21.1 21.4 21.7 22.4 21.9 0.1 23.5 21.9
A144 20.7 20.6 21.2 20.8 21.2 20.4 20.9 21.3 20.8 20.6 21.7 20.9
D145 1.3 20.1 6.3 0.3 4.0 20.4 4.7 1.1 2.0 0.6 20.4 20.9
245.3 227.8 241.1 260.2 257.6 258.1 237.3 272.5 282.0 240.3 251.7 256.7
a M and C refer to monomeric (inactive) and cyclin bound (active), respectively.
b Values in bold indicate a more favorable interaction with active CDK2; italicized values indicate a more favorable interaction with monomeric
CDK2.Pyrimidine Contacts
The core pyrimidine ring makes similar contacts in both
monomeric and cyclin bound CDK2 structures. E81 gen-
erally makes a greater contribution to binding of the li-
gand in the active enzyme, with the exception of 1 and
6. Close contacts are observed in several of the mono-
meric-ligand complexes, resulting in offsetting of the en-
thalpy gain from the CH:O H bond from the pyrimidine
ring to the E81 backbone carbonyl.Thiazole Region
The pocket that accommodates the thiazole systems of
the inhibitors includes both hydrophobic (V18, F80) and
polar residues (N132, D145). In all structures, F80 makes
similar or greater contributions to ligand binding in the
active context. Inhibitors 3 and 4 exhibit the most signif-
icant favorable change with respect to the cyclin bound
CDK2 as a consequence of the movement of F80 to ac-
commodate E51 upon activation. The most dramaticFigure 3. Crystal Structures of Ligands 1 and
4 Bound in Active and Inactive CDK2
(A–C) The overlay shown is residues 77–143
of the same inhibitor (yellow, active; blue, in-
active) and with the substituted aniline deriv-
ative 4 (yellow) bound in (B) monomeric
CDK2 (green) and (C) active (pink) CDK2.
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nomeric CDK2 Binding Modes of Pyrimidine
Inhibitors 3, 5, and 6
(A) Inhibitor 3 bound in the ATP binding site
of active (yellow) and inactive (blue) CDK2
showing the large shift of Y15 in the active
CDK2 structure.
(B) The structures of ligand 5 bound in active
(yellow) and inactive (blue) CDK2, overlaid
from residues 77–143.
(C) The phenyltriazole group of ligand 6 oc-
cupies a different conformation depending
on which activation state of CDK2 it is bound
to and makes substantially different interac-
tions with the binding site in each context.changes in this region are involve contributions of D145
to binding of the ligand. With all five thiazole-containing
ligand structures of inactive CDK2, interactions with this
residue are detrimental to binding (unfavorable energies
ranging from +1.3 to +6.3 kcal/mol) as a result of the
close proximity of D145 to the inhibitor. Clashes of the
thiazol-2-yl-methyl group and the ring nitrogen with the
carboxylate are responsible for the unfavorable contri-
butions. Contacts with the side chain of D145 in the
active complexes are significantly more favorable, with
observed differences resulting in rotation of the carbox-
ylate group about the Cb-Cg bond.
Other significant differences observed in the struc-
tures of inhibitors 2–5 are in the positions of Y15 and
K33. Y15 undergoes a relative change in position in
most of the structures; however, only for compound 3
does it move by 10 A˚ into the ligand binding site in the
CDK2/cyclin A structure. For K33, in each of the mono-
meric complexes the side chain amine projects away
from the ligand, whereas, in the active structures, it is
much closer to the thiazole ring nitrogen. This movement
generally creates a more open pocket in the active CDK2
structures.
Compound6 (thiazole substituent replaced with a ben-
zyl-triazole) is a unique structure in this series, and of the
ligands presented here, it shows the most significant dif-
ferences in binding to monomeric and active CDK2
(Figure 4C; Table 2) due to the bulkier ‘‘head group’’ ex-
tending further into the phosphate binding domain. In
the monomeric complex, the triazole ring projects per-
pendicular from the phenyl toward the Gly-rich loop. In
the active CDK2 structure, the triazole shifts by more
than 2.5 A˚ and interacts extensively with D145, an inter-
action facilitated by the relative shifts of K33 and D145.
This is not possible in the monomeric context due to
the overlap of the benzyl-triazole group with K33. An-
other consequence of the enforced alternate triazole
conformation in the monomeric enzyme is the relative
movement of the phenyl replacement for the thiazole
(Figure 4C). This results in effective contacts of the phe-nyl in the monomeric context with V18 and of the pyrim-
idine ring with L134 (21.4 and21.6 kcal/mol more favor-
able, respectively).
In order to examine the differences in protein/ligand
interactions for CDK2 inhibitor complex structures that
have been deposited in the PDB, a data-mining exercise
was performed examining the contact information for
compounds with a reported IC50 against CDK2 of 1 mM
or less. The results of the comparison (Table 4) indicate
that there are substantial differences in the average
number of contacts for residues in the two activation
states. Table 4, section A, shows that the PDB ligands
in monomeric CDK2 interact more extensively with the
side chains of D145 and A144 and the backbone atoms
of I10, F82, and L83 (higher ratio of monomeric to active
CDK2/ligand contacts). The ligands in complex with
CDK2/cyclin A, however, make more contacts with the
Gly-rich loop backbone (G11, E12, G13) and also with
the side chains of K33, V64, and F82 (Table 4, section
B, higher ratio of active to monomeric CDK2/ligand con-
tacts).
Discussion
Implications of Differential CDK2 Inhibitor Binding
for Drug Design
The detailed comparison of inhibitors bound to the inac-
tive and active conformations of CDK2 presented here
has demonstrated that differences in binding mode
can be observed, and that these result in substantially
different ligand affinities. The use of the monomeric
structural data for ligand design [14, 31, 32] therefore
contrasts with that obtained from biological assays
since these are based on activated CDK2. Interpretation
and evaluation of structural data is therefore often ex-
trapolated from the monomeric to active contexts. Pre-
viously, a detailed comparison of diverse ligands bound
to both active and inactive forms of CDK2 had not been
completed, although some structural information is
available [24–26, 29]. In the PDB, there is only one ligand,
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207NU2058, for which a complex crystal structure has been
solved with both CDK2 and CDK2/cyclin A. Indirubin-5-
sulfonate has previously been shown to bind in similar
conformations in monomeric and binary CDK2 and
makes common interactions with both states [26]. One
of the residues that shifts most significantly upon activa-
tion, D145, adopts a rotamer state more similar to that in
the monomeric structure, although there is anw1 A˚ shift
in the position of this side chain. Further direct compar-
isons of this ligand bound to monomeric and active
CDK2 were not possible since only one set of coordi-
nates was deposited in the PDB.
The new data presented therefore extend and further
illustrate that significant differences in protein/ligand in-
teractions are observed between the two states of
CDK2, and, therefore, due care should be taken in the
structure-guided discovery and design of kinase inhibi-
tors. These data demonstrate that diverse CDK2 phar-
macophores can make quite different interactions in
monomeric structures routinely used for informing li-
gand design when compared to the active enzyme.
This is especially true for inhibitors 1 and 6, in which in-
Table 4. Comparison of Protein/Ligand Contacts for CDK2 in the
Monomeric and Active Forms
CDK2A CDK2 Monomer
A
Number
of
Contacts Average
Number
of
contacts Average
Average
Monomeric/
Active
A144 CB 2 0.1 16 0.9 6.2
F82 C 2 0.1 11 0.6 4.3
D145 OD2 11 0.8 60 3.3 4.2
K89 CA 2 0.1 10 0.6 3.9
F82 CA 5 0.4 22 1.2 3.4
I10 O 3 0.2 12 0.7 3.1
D145 CG 6 0.4 20 1.1 2.6
L83 CA 4 0.3 13 0.7 2.5
F80 CE 4 0.3 11 0.6 2.1
F82 CD 8 0.6 19 1.1 1.8
D145 CB 7 0.5 15 0.8 1.7
Q131 O 8 0.6 16 0.9 1.6
B
Average
Active/
Monomeric
E12 N 10 0.7 1 0.1 12.9
G11 C 10 0.7 2 0.1 7.1
E12 C 11 0.8 3 0.2 4.7
G13 N 9 0.6 3 0.2 3.9
D145 N 9 0.6 3 0.2 3.9
G12 O 9 0.6 3 0.2 3.9
G13 CA 14 1.0 7 0.4 2.6
Q85 CA 34 2.4 19 1.1 2.3
N132 OD1 15 1.1 9 0.5 2.1
G11 CA 8 0.6 5 0.3 2.1
F82 CZ 9 0.6 6 0.3 1.9
F82 CE 25 1.8 17 0.9 1.9
D86 N 19 1.4 13 0.7 1.9
K33 CE 10 0.7 8 0.4 1.6
K33 NZ 10 0.7 8 0.4 1.6
V64 CG 23 0.8 18 0.5 1.6
F80 CB 24 1.7 20 1.1 1.5
K89 CD 19 1.4 17 0.9 1.4
F80 CD 29 2.1 26 1.4 1.4
I10 CG2 57 2.0 55 1.5 1.3
Sections A and B indicate the CDK2 atom with the higher average
number of contacts in the monomeric and active forms, respectively.terpretations from the binary ligand complex would
quite possibly be misleading (Figures 3 and 4C). Com-
pound 1 is the most dramatic example, and, in this
case, the low-affinity inhibitor (an initial screening hit)
undergoes a 180º rotation in binding mode (Figures
3A–3C). Structure-based design with the monomeric in-
formation could result in the wrong analogs being syn-
thesized in the early stages of lead optimization against
activated CDK2, with potentially detrimental conse-
quences.
For the inhibitors studied that have a similar binding
mode in both the monomeric and cyclin bound CDK2,
the ligand contacts with the Gly-rich loop and the side
chains of K33 and D145 vary significantly. From obser-
vations of the unliganded structures of CDK2, rotation
of the PSTAIRE helix upon cyclin binding results in
movement of E51 into, and L148 out of, the ATP binding
site. As a result, the ion-pairing interaction between K33
and D145 is broken, and the latter residue projects away
from the cleft, while K33 now forms a new salt bridge
with E51. These changes result in differing interactions
of the inhibitor with K33 and D145 in the novel active li-
gand structures presented here and more favorable con-
tributions of D145 to inhibitor binding.
This is illustrated most dramatically in the structures of
inhibitor 6. This analog displays significantly different in-
teractions of the benzyl-triazole moiety with the ATP
pocket (Figure 4C). The triazole conformation of the
CDK2/cyclin A bound ligand cannot be accommodated
with the positions of K33 and D145 observed in the mo-
nomeric enzyme, and it is displaced toward the Gly-rich
loop. The observed displacement leads to a different set
of interactions of the triazole and more optimal hydro-
phobic contacts of the inhibitor as a whole, with the
energetic analysis showing that it binds more tightly to
inactive CDK2. The differences in binding mode suggest
that structure-guided optimization against cyclin-
activated CDK2, with crystallography of the inactive
enzyme, could lead to erroneous interpretations of
structural data. These observed differences for inhibitor
6 are likely to be true for all CDK2 ligands that interact
with the phosphate binding region.
Even for the case in which ligands bind with similar
conformations in both contexts, the inactive CDK2
structure may still provide inadequate or misleading in-
formation. Analysis of the monomeric crystal structure
of inhibitor 4 did not adequately explain the structure-
activity relationship that had been determined by using
an in vitro kinase assay. In particular, replacement of
the 2-methyl group of the thiazole ring with an amino
function resulted in a 100-fold potency enhancement
[27], although the inactive crystal structure of this analog
did not reveal a favorable interaction of the amino group.
Solution of the CDK2/cyclin A/4 complex showed that
the ligand NH2 donates an H bond to the D145 carboxyl-
ate; therefore, the position of this residue in inactive
CDK2 did not accurately resolve the structure-activity
relationship of the inhibitor described experimentally.
This is further illustrated by comparing the structures
of 5, for which a significant movement of the thiazole
ring occurs. Unfavorable interactions of the aniline sub-
stitution and the resulting displacement of the thiazole
system leads to inaccessibility of the thiazole 2-amino
group on the thiazole for H bond formation to D145.
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icant differences were observed for Y15; however, even
in the case of the largest movement of this residue (com-
pound 3, Figure 4A), a minimal contribution to inhibitor
binding occurred (Table 3). The possibility that this resi-
due may impact structure-guided design should there-
fore be considered in some contexts.
The observations made on the basis of the six inhibi-
tors whose crystal structures were solved in both the in-
active and activated CDK2 forms have been supported
by the analysis of protein/ligand interactions in the li-
gands obtained from the PDB. Through the contact anal-
ysis method, significant general differences have been
described (Table 4), indicating that the contact profiles
obtained in the pyrimidine comparison are not specific
for this pharmacophore. The ligands of the PDB inhibitor
set make predominant contacts with the Gly-rich loop in
the active enzyme, consistent with the different confor-
mation of this region of CDK2 and with the observations
described for our compounds. Also, as indicated in the
pyrimidine inhibitor structures, the PDB ligands in the in-
active CDK2 contain multiple contacts with the D145
side chain. Many of these contacts are overlapping
and also are not observed in the active complexes.
Also, consistent with the new ligands presented are
the different interactions with the hinge region backbone
in both contexts and the contacts observed with I10. The
marked increase in contacts to V64 in the active struc-
tures in comparison to the monomeric structure is sur-
prising, as this was not observed with our pyrimidine in-
hibitors, although this may be the result of unique
interactions of this series.
The differences in ligand binding mode and energetics
described in the two forms of CDK2 are mainly caused
by conformational differences in the binding site. As
has been shown, this depends on the size and comple-
mentarity of the inhibitor and the way in which the basic
pharmacophore template of the inhibitor is functional-
ized. As we have observed, the smaller ligand 1 (Fig-
ure 3A) more easily adopts a different conformation in
order to compensate for the differences in the binding
site between monomeric and cyclin bound CDK2. Larger
ligands cannot easily adopt alternate conformations
since these may result in more extensive, unfavorable in-
teractions in the binding site (Figures 3B and 3C). In ad-
dition, unfavorable side chain conformations that may
occur would not override favorable ligand binding en-
thalpies; however, they will decrease the overall affinity
of the ligand in either context. In the pyrimidine series,
this applies to ligands with a substituted aniline nitrogen
(compounds 2–6) since adjustment of the conformation
of the inhibitor would result in atom overlap with H84,
Q85, and K89. These ligands could not adopt similar
conformations compared to 1 in the monomeric CDK2,
as this would result in steric clashes with atoms of F80
and E81 (Figure 3B). These observations thus further un-
derline the necessity to compare liganded structures of
CDK2 in both inactive and active contexts. The applica-
tion of these results in drug discovery and optimization
therefore indicates that caution should be exercised in
the context in which structural information for an inhibi-
tor is obtained. Our results show that if active CDK2 is
used for in vitro screening, then structural information
should be interpreted accurately on the basis of thesedata. Although monomeric CDK2 structures require
less effort and are generally obtained to higher resolu-
tion, it would be expedient to obtain at least one active
ligand complex structure in order to confirm and further
inform the structure-activity relationship observed from
the CDK2/cyclin kinase assay.
Consequences of Structural and Affinity Differences
for In Silico Screening
Due to the observed differences in ligand binding to ac-
tive CDK2 complexes, the use of monomeric structures
as templates for high-throughput docking may not pro-
duce the best results. Although virtual screening can un-
doubtedly lead to enrichment over random screening
methods [28], further improvements in hit rates should
be obtained though inclusion of an active CDK2 struc-
ture in the docking stage. Even in the situation in which
a ligand binds similarly in both structural forms (Figures
4A and 4B), the ligand would probably not be scored cor-
rectly, since, as shown, measured interaction energies
do not correlate with binding in the monomeric protein.
Docked poses would therefore likely be incorrectly
ranked in the inactive CDK2, resulting in inaccurate pre-
dictions of small-molecule inhibitor binding. If in silico
screening is to be performed on the inactive CDK2, our
data suggest that the best results would be obtained
only if experimental binding constants were determined
with an assay based on the monomeric kinase.
A recent study from this laboratory examined the influ-
ence of CDK2 structure on the extent of successful re-
production of crystallographic binding mode by high-
throughput docking programs [33]. The conclusions
drawn were that the positioning of side chains, and the
volume of the binding site, are the critical factors in de-
termining how many ligands dock with the correct
pose, and that use of the activated CDK2 structures re-
sults in the most success in this regard. This study con-
firms the observations that the positions of the side
chains of K33, F80, K89, and D145 are important, as is
that of the Gly-rich loop.
Prospects for Selectively Targeting Inactive
CDK Conformations
The results presented here also have implications for in-
hibitor design aimed at preferentially targeting kinase
structures that are in the inactive form. Recently, several
complex crystal structures of protein kinase inhibitors
have demonstrated that predominant binding to inactive
conformations can be crucial to their mode of inhibition
[34]. Binding in these instances produced highly selec-
tive ligands, since inactive kinase structures are often
unique in terms of their interactions with the ligand in
comparison to the active ones. The results presented
here from the energetic analysis of CDK2 inhibitors in
both their binary and ternary complexes suggest that it
is feasible to generate potent CDK2 inhibitors that bind
with significantly higher affinity to the inactive conforma-
tion of this enzyme. Some inhibitors make tight interac-
tions with D145 and therefore stabilize the inactive con-
formation. A positive outcome of this is that ligands that
have greater specificity for the inactive CDK2 can, in
principle, be designed. Energetic analysis showed that
the affinity of ATP for the inactive enzyme is considerably
greater than that observed for the cyclin-complexed
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could be explained by the fact that exposure of the
g-PO4 (buried in the monomeric structure) is required
for catalytic phosphotransfer to occur. Consequently,
many interactions with the g- and b-phosphates ob-
served in the monomeric structure are not present in
the active form. Analysis of the ATP bound structures
in which the g-phosphate required for catalysis is buried
suggests that further targeting the phosphate binding
region could result in highly selective binding to the inac-
tive CDK2 conformation.
We have shown previously that CDK2 inhibitors in-
duce significant disordering of the T-loop when bound
to the monomeric protein [28]. Displacement of K33
from the salt bridge with D145 results in movement of
the Gly-rich loop and subsequent activation loop disor-
dering. In the context of these results, it is conceivable
that where inhibitors bind tightly to the monomeric
CDK2 and sequester it in this form, they could prevent
activation by the cyclin molecule in a particular cell cycle
compartment. Specificity of inhibitors for the inactive
CDK2 conformation should also result in a greater selec-
tivity for this kinase as a target in the cellular context, as
the ATP binding site would be in a more distinct con-
formation, although this would not be reflected in the
in vitro kinase assay. Competitive binding assays with
fluorescently labeled inhibitors that allow quantification
of direct binding to protein kinases could be used to de-
termine affinity for both active and inactive conforma-
tions of CDK2. Selectivity for monomeric CDK2 would
also be applicable to inhibiting any cyclin-independent
kinase activity associated with phosphorylated protein
[21]. The significant level of kinase activity of the phos-
phorylated monomeric protein is likely to be biologically
relevant given that the CDKs are present throughout the
cell cycle and are only transiently activated by cyclins.
The results obtained in this study thus warrant additional
experiments comparing binding to inactive and active
CDK2 with the potential aim of selectively targeting
these conformations.
Significance
Through comparison of a number of new CDK2 inhib-
itor structures we have demonstrated that ligand-
protein kinase interactions and conformations vary
substantially between the active and inactive forms.
Energetic analysis of these inhibitors bound to both
monomeric and binary CDK2 forms has revealed de-
tails of the differences in inhibitor binding mode and
induced protein changes. These differences were ad-
ditionally confirmed through extraction of CDK2 inhib-
itor protein-ligandcontact information fromaselection
of potent inhibitors whose structures were previously
solved in either the monomeric or active forms. Calcu-
lation of the intermolecular binding energies from the
crystal structures has demonstrated that while themo-
nomeric CDK2 ligand complexes are not reflective of
the experimentally obtained inhibition constants, the
CDK2/cyclin A bound inhibitor structures correlate
accurately with the in vitro assay data. These results
have significant implications for structure-based li-
gand discovery and design in that, if the key differ-
ences in interactions are accounted for with in silicoscreening and inhibitor optimization, then an enhance-
ment in success criteria should be obtained. The anal-
ysis also indicates that ligands can potentially be
designed selectively to target the inactive conforma-
tion of CDKs, and that thismay result inmore selective
ligands being obtained.
Experimental Procedures
Human recombinant CDK2 and human recombinant cyclin A2 (frag-
ment encompassing residues 173–432) were expressed, purified,
and crystallized as previously described [28, 35]. Biochemical as-
says were carried out as reported previously [36, 37].
Structure Determination
Data were collected at the Daresbury (UK) and Grenoble (France)
synchrotron facilities by using an ADSC Quantum4 CCD detector
and home with a Raxis IV++ image plate (Rigaku). Data processing
was carried out with the programs DENZO and SCALEPACK [38],
or the d*TREK software suite [39] or MOSFLM [40] and SCALA [41]
from the CCP4 program suite [42]. Data often showed signs of crys-
tal radiation damage. The structures were solved by molecular re-
placement with MOLREP [43] and PDB entries 1PW2 and 1OKV as
the search models for CDK2 and CDK2/cyclin A, respectively.
ARP/wARP [44] was used for initial density interpretation and the
addition of water molecules. REFMAC [43] was used for structural
refinement. A number of rounds of refinement and model building
with the program Quanta (Accelrys, San Diego, CA) were carried out.
Computational Chemistry
Calculation of protein/ligand interaction energies between inhibitor
and CDK2 or the CDK2/cyclin A complex was performed by using
the AFFINITY module after addition of hydrogens and 200 steps of
steepest-descent minimization with the program DISCOVER of the
modeling package InsightII (Accelrys). As heavy atoms of the protein
and ligand were fixed, the minimization was performed to relieve
high energies as a result of hydrogen addition to the crystal struc-
tures. Affinity measures the van der Waals and electrostatic intermo-
lecular energies. The ligscore1 and LUDI scoring functions of the
Cerius2 program (Accelrys) were also used in order to determine in-
hibitor binding energy. The analysis of CDK2 inhibitor intermolecular
contacts from the PDB (Table 4) was carried out by extracting all pro-
tein/ligand contacts less than 4 A˚ on an atomic basis by using the
program Quanta (Accelrys). Structures of monomeric and active
CDK2 structures from the PDB having an IC50 value of less than
1 mM were used for this analysis. For each set of monomeric and ac-
tive structures, the total number of contacts for each protein atom
within the distance cutoff was generated and subsequently aver-
aged over all structures. In order to facilitate comparison between
monomeric and active liganded structures, tables were sorted ac-
cording to the total number of contacts per atom and the number
of contacts averaged over all of the structures in each category.
Synthesis
Preparations of compounds 1–5 were previously described [27].
3-Nitro-phenyl-[4-(3-[1,2,4]triazol-1-ylmethyl-phenyl)-
pyrimidin-2-yl]-amine
A mixture of 3-dimethylamino-1-(3-[1,2,4]triazol-1-ylmethyl-phenyl)-
propenone and 1.5 molar equivalents each of 3-nitro-phenyl guani-
dine nitrate and NaOH in 2-methoxylethanol was heated at 125ºC
for 20 hr. The solvent was evaporated, and the residue was purified
by silica gel chromatography by using elution with EtOAc and then
EtOAc/MeOH (10:1) to afford the title compound as a yellow solid
(yield 50%). Anal RP-HPLC (Vydac 218TP54 2503 4.6 mm columns,
linear gradient elution with H2O/MeCN systems containing 0.1%
CF3COOH at a flow rate of 1 ml/min): tR = 17 min (0%–60% MeCN,
purity 99%; 1H-NMR (500 MHz, DMSO-d6): d 5.54 (s, 2H, CH2), 7.43
(d, 1H, J = 8.0 Hz, Ph-H), 7.51 (d, 1H, J = 5.0 Hz, pyrimidine-H),
7.54 (t, 1H, J = 8.0 Hz, Ph-H), 7.58 (t, 1H, J = 8.0 Hz, Ph-H), 7.81 (d,
1H, J = 8.0 Hz, Ph-H), 7.98 (s, 1H, Ph-H), 8.07 (d, 1H, J = 8.0 Hz,
Ph-H), 8.15 (d, 1H, J = 8.0 Hz, Ph-H), 8.21 (s, 1H, Ph-H), 8.65 (d, 1H,
J = 5.0 Hz, pyrimidine-H), 8.70 (s, 1H, triazol-H), 9.11 (s, 1H, triazol-H),
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21010.27 (s, 1H, NH). MS (ESI+) m/z 374.4 [M+H]+, C19H15N7O2 requires
373.37.
3-Dimethylamino-1-(3-[1,2,4]triazol-1-ylmethyl-phenyl)-
propenone
A solution of 1-m-tolyl-ethanone (5.0 g, 37.3 mmol) in anh. MeCN
(45 ml) was treated with N-bromosuccinimide (6.63 g, 37.3 mmol)
and benzoyl peroxide (9.02 g, 37.3 mmol). The reaction mixture
was heated at 80ºC for 6 hr. Upon cooling, the mixture was concen-
trated, and the resulting syrup was dissolved in Et2O and treated
with NaHCO3. The ethereal layer was washed with brine and dried
on MgSO4. The solvent was evaporated, and the resulting residue
was purified by silica gel chromatography (heptane/EtOAc 12:1–
3:1) to afford 1-(3-bromomethyl-phenyl)-ethanone (5.5 g, 69%). 1H-
NMR (CDCl3): d 2.54 (s, 3H, CH3), 4.45 (s, 2H, CH2), 7.38 (t, 1H, J =
8.0 Hz, Ph-H), 7.52 (d, 1H, J = 8.0 Hz, Ph-H), 7.81 (d, 1H, J = 8.0 Hz,
Ph-H), 7.90 (s, 1H, Ph-H).
1H-[1,2,4]triazole (0.15 g, 2.25 mmol) in anh. DMF (8 ml) was cooled
on an ice bath and treated with Cs2CO3 (0.67 g, 2.07 mmol). After stir-
ring for 30min, 1-(3-bromomethyl-phenyl)-ethanone (0.4 g, 1.88mmol)
was added. The reaction mixture was warmed to room temperature
and was stirred for 20 hr. Ice water was added, and the mixture was
extracted with Et2O. The combined extracts were washed with brine
and dried on MgSO4. The solvent was evaporated, and the residue
was purified by silica gel chromatography by using heptane/EtOAc
(12:1–3:1) to afford 1-(3-[1,2,4]triazol-1-ylmethyl-phenyl)-ethanone
(0.23 g, 60%). 1H-NMR (CDCl3) d: 2.58 (s, 3H, CH3), 5.39 (s, 2H,
CH2), 7.45 (d, 1H, J = 7.5 Hz, Ph-H), 7.47 (t, 1H, J = 7.5 Hz, Ph-H),
7.87 (s, 1H, Ph-H), 7.92 (d, 1H, J = 7.5 Hz, Ph-H), 7.97 (s, 1H, triazol-H),
8.11 (s, 1H, triazol-H).
An aliquot of this material (0.10 g, 0.50 mmol) was treated withN,N-
dimethyl formamide dimethylacetal (1 ml, 8.39 mmol) at 100ºC for
7 hr. Upon cooling, the reaction mixture was concentrated, and the
resulting residue was purified by silica chromatography by using
heptane/EtOAc (3:1–1:10) to afford 3-dimethylamino-1-(3-[1,2,4]tria-
zol-1-ylmethyl-phenyl)-propenone as a yellow solid (80% yield). 1H-
NMR (CDCl3) d: 2.89 (s, 3H, CH3), 3.12 (s, 3H, CH3), 5.45 (s, 2H, CH2),
5.76 (d, 1H, J = 12.5 Hz, CH), 7.35 (d, 1H, J = 8.0 Hz, Ph-H), 7.40 (d, 1H,
J = 8.0 Hz, Ph-H), 7.70 (d, 1H, J = 12.5 Hz, CH), 7.79 (s, 1H, Ph-H), 7.82
(d, 1H, J = 8.0 Hz, Ph-H). 7.97 (s, 1H, triazol-H), 8.67 (s, 1H, triazol-H).
Supplemental Data
Supplemental Data including Table S1 (crystallographic data and
statistics) and Figure S1 (schematic representation of the CDK2
binding mode of compounds 2–5) are available at http://www.
chembiol.com/cgi/content/full/13/2/201/DC1/.
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